Ailomics Therapeutics Secures Tens of Millions in Angel Funding to Advance Novel Target Discovery and Innovative Drug Development

VCBeat learned第一时间 that recently,Ailomics Therapeutics Co., Ltd(Ailomics Therapeutics) (hereinafter referred to as“Ailomics”) Announced CompletionTens of Millions of Angel RoundFinancing, byQiming Venture PartnersLeading investment,SanyiInnovation InvestmentAndHua Tong CapitalFollow-on Investment. The funds raised this time will be used for the construction of core technology platforms and the advancement of the R&D pipeline.

Ailomics was founded in July 2022 and is aA Startup Company Dedicated to Innovative Drug Development。AilomicsAilomics leverages its groundbreaking computational biology platform to conduct in-depth analysis of multi-omics data from patients, identifying new mechanisms and drug targets that drive disease progression, and developing innovative drugs.Based on a deep understanding of disease biology, Ailomics is committed to innovative drug research and development for immune diseases and tumors with significant clinical needs.

With the completion of this round of financing, Ailomics will build a comprehensive technology platform integrating next-generation computational biology, experimental biology, and antibody development. By leveraging AI technologies such as Deep Learning to systematically analyze patients' multi-omics big data (including single-cell and spatial omics), the company aims to identify key cell types and intracellular/extracellular signaling pathways that drive disease progression. This will enable the selection of promising new targets addressing significant clinical needs for the development of First-in-class drugs. Ailomics has established a new drug research and development center in Shanghai's Zhangjiang Pharm Valley and will build an innovative drug pipeline with international competitiveness through independent research and collaboration with top clinical principal investigators (PIs) in China.

The core founding team of Ailomics has many years of experience in new drug research and development at international pharmaceutical giants.Dr. Qing Zhang, Founder and CEO of AilomicsWorked for 14 years at GlaxoSmithKline (GSK), Amgen, and Roche, utilizing computational methods for small molecule and antibody drug design, target discovery, and validation, and is a co-inventor of three clinical candidate drug molecules.Dr. Ding Yao, Co-founder of the CompanyPreviously worked at Hengrui, Amgen, and BeiGene, with over 10 years of experience in antibody research and development.Co-founder Dr. Ban TingPreviously worked at Roche and Amgen, with experience in early-stage equity investment and incubation in biopharmaceutical companies.

Dr. Qing Zhang, Founder of AilomicsStated: "We are very grateful for the trust of our investors, supporting us in discovering new targets in the industrial sector and practicing the new drug development model from clinical to research and back to clinical (from bedside to bench and to bedside again). The biology of diseases is complex, and we will utilize rapidly advancing sequencing technologies and data science, combined with a large number of highly concentrated clinical samples in China, to digitize and create AI models of disease biology. To further enhance the clinical translation success rate of new drugs, we will 'humanize' new drug research by establishing a human disease model platform, including organ-on-chip technology. We welcome computational biologists, immunologists, and antibody engineering scientists who share a similar vision to join Ailomics."

Dr. Chen Kan, Partner of Qiming Venture PartnersSaid: "Qiming Venture Partners has always paid close attention to innovative companies in the biopharmaceutical field. Ailomics utilizes cutting-edge digital and artificial intelligence technologies to decode complex disease biology, pioneering a new paradigm in drug development. The company's founding team possesses extensive experience in computational biology, experimental biology, as well as corporate management and operations. Globally, there are significant unmet needs in the fields of immunological diseases and oncology, and we look forward to Ailomics Therapeutics bringing new hope to patients soon."

Dr. Ian Yin, Managing Partner of Beijing Baixun Investment Management Co., Ltd.Said: "In recent years, the rapid development of single-cell sequencing technology and computational biology has significantly increased the success rate of drug development targeting new targets and mechanisms. The three outstanding founders, based on their long-term professional accumulation and forward-looking understanding of the industry, established Ailomics. Ailomics possesses a unique computational biology platform. We believe that with the team's years of R&D experience and prominent platform technology, they can quickly build an internationally competitive innovative drug R&D pipeline around immune diseases and cancer, serving unmet clinical needs."

Huatong Capital Investment TeamStated: "The development of new drugs is a difficult process with high risks, long cycles, and high costs. Currently, artificial intelligence has been implemented in the biopharmaceutical industry from upstream to downstream, gradually becoming a core component of the industry. Ailomics combines single-cell multi-omics sequencing technology with artificial intelligence algorithms to digitize disease biological data, explore new mechanisms of action, and increase the success rate of new drug development. In its research areas, the market space for drugs targeting immune diseases and cancer is enormous. Some diseases lack effective treatments due to unclear mechanisms, creating opportunities for new drug discoveries to fill these market gaps. Huatong Capital highly recognizes the Ailomics team for its independent data generation and exploration capabilities, which are expected to uncover new mechanisms and drug targets within these fields, develop innovative drugs, and benefit more patients."

Qiming Venture Partners was founded in 2006 and has successively established offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages 11 US dollar funds and 7 RMB funds, with total managed assets under management reaching 9.4 billion US dollars. Since its establishment, it has focused on investing in outstanding companies in the early and growth stages of the Technology and Consumer (T&C) and Healthcare industries. To date, Qiming Venture Partners has invested in more than 480 rapidly growing innovative enterprises, of which over 180 have been listed or exited through mergers on exchanges such as the New York Stock Exchange, NASDAQ, the Hong Kong Stock Exchange, the Shanghai Stock Exchange, and the Shenzhen Stock Exchange. More than 70 of these enterprises have become unicorns or super unicorns recognized within their respective industries.

Beijing Baixun Investment Management Co., Ltd. ("Baixun Investment") is a private equity venture capital firm focused on pharmaceutical innovation. The fund contributors include well-known enterprises in the pharmaceutical industry and prominent investment institutions in the financial sector. Baixun Investment adheres to the belief of "scientists, professional managers, and investors working as one, with professionals handling professional tasks, serving health through science." By leveraging capital ties, it integrates resources to support scientists in transforming their research achievements, helps professional managers build entrepreneurial platforms, fosters a group of innovative biopharmaceutical enterprises, and enables science to serve health and benefit patients. Baixun Investment is committed to growing together with its invested companies and entrepreneurs, utilizing industry experience and available resources to help these companies maximize the value of their technologies.

Huatong Capital is an investment institution focused on the medical device and biopharmaceutical fields, investing in early-stage companies with core technologies and great potential, as well as some growth-stage companies with strategic layouts. Huatong Capital boasts a multidisciplinary team comprising professionals from medical device R&D, clinical doctors, and life science researchers. Professionalism and focus are our hallmarks. Since its establishment, it has invested in (or incubated) several outstanding companies. With steady and rapid development, we are committed to becoming one of the most promising young venture capital firms.